α-GlcNAc and its catalyst α4GnT are diagnostic and prognostic markers in uterine cervical tumor, gastric type

Koichi Ida¹, Kazuhiro Yamanoi²,³,⁴, Shiho Asaka⁵, Hodaka Takeuchi¹, Tsutomu Miyamoto¹, Tanri Shiozawa¹ & Jun Nakayama²,³

Cervical adenocarcinoma, gastric type (GAS) is not associated with human papilloma virus (HPV) infection. GAS patients' prognosis is significantly worse compared with cervical adenocarcinoma associated with HPV infection, as their tumors exhibit resistance to conventional chemotherapy and radiotherapy. GAS is often associated with lobular endocervical glandular hyperplasia (LEGH), which is regarded as a precursor to GAS in the latest WHO classification. Recently, we reported that a decrease in expression of terminal α1,4-linked N-acetylglucosamine (αGlcNAc) relative to that of MUC6 was already apparent in atypical LEGH in the LEGH-GAS sequence. Here, we analyzed expression of α1,4-N-acetylglucosaminyltransferase (α4GnT), the sole enzyme catalyzing αGlcNAc biosynthesis, and that of αGlcNAc and MUC6 in cases representing non-neoplastic endocervical gland (NNEG) (11 cases), LEGH (26 cases) and GAS (12 cases). α4GnT protein was detected in a “dot-like” pattern, indicating localization in the Golgi apparatus in all 26 LEGH cases and 5 of 12 GAS cases. α4GnT- and αGlcNAc-positive cells largely overlapped, suggesting that α4GnT gene expression regulates αGlcNAc biosynthesis. Interestingly, all NNEG cases were negative for α4GnT and αGlcNAc expression, but 7 of 11 NNEG and all LEGH cases were MUC6-positive. In GAS cases, patients whose tumors were α4GnT- and αGlcNAc-positive had more favorable prognosis than others. Multivariate analysis revealed that positive expressions of α4GnT and αGlcNAc could serve as independent prognostic indicators. These results indicate that α4GnT and αGlcNAc could serve as useful markers not only to distinguish LEGH from NNEG but to evaluate prognoses of GAS patients.
We previously analyzed alterations in specific sugar residues of gastric gland mucin in relationship to cancer progression. Gastric gland mucin contains O-linked oligosaccharides (O-glycans) with terminal α1,4-linked N-acetylglucosamine (αGlcNAc) residues attached largely to a MUC6 scaffold. Previously, we isolated cDNA encoding α1,4-N-acetylgalactosaminyltransferase (α4Gnt), the enzyme catalyzing αGlcNAc biosynthesis, and then generated A4gnt-deficient mice. These mutant mice showed αGlcNAc loss in gastric gland mucin and naturally developed gastric adenocarcinoma through a hyperplasia-dysplasia-carcinoma sequence without Helicobacter pylori infection. We also evaluated αGlcNAc expression in human gastric adenocarcinoma and pyloric gland adenoma, which precedes gastric adenocarcinoma, and observed frequent loss of αGlcNAc expression in MUC6-positive differentiated-type adenocarcinoma and high-grade pyloric gland adenoma. These results indicate that αGlcNAc functions as a tumor suppressor in gastric cancer.

In concordance with the idea, we evaluated α4Gnt and MUC6 expression in gastric gland mucin-producing tumors arising in extra-gastric organs. In pancreas, we observed significantly decreased αGlcNAc expression relative to MUC6 not only in invasive carcinoma but in its pre-malignant lesions, intraductal papillary mucinous neoplasm and pancreatic intraepithelial neoplasia. Furthermore, we recently reported that αGlcNAc and MUC6 are co-expressed in typical LEGH, but αGlcNAc expression is reduced relative to MUC6 in atypical LEGH and minimal deviation adenocarcinoma (MDA). These findings support the idea that reduced αGlcNAc expression relative to MUC6 marks progression from pre-malignant lesions to cancers showing pyloric gland phenotypes in stomach, pancreas and uterine cervix and that αGlcNAc functions as a tumor suppressor. However, the expression pattern of α4Gnt, which is responsible for αGlcNAc biosynthesis, in tumors arising from uterine cervix has not been assessed, and αGlcNAc expression related to GAS prognosis is unclear. Furthermore, MUC6, αGlcNAc and α4Gnt expression in non-neoplastic endocervical gland (NNEG) has not been fully characterized.

In this study, we extend our previous studies and perform immunohistochemical assessment of expression of gastric gland mucin-related markers, including α4Gnt, as well as αGlcNAc and MUC6 in LEGH, GAS and NNEG lesions. We also analyze potential associations between marker expression and prognosis and clinicopathological factors relevant to GAS. We report that α4Gnt and αGlcNAc could serve as useful markers not only to distinguish LEGH from NNEG but to estimate prognosis of GAS patients.
Materials and Methods

Patients and tissue samples. Ethical approval was granted by the Institutional Review Board at Shinshu University School of Medicine, Matsumoto, Japan in accordance with the Declaration of Helsinki (no. 3996). Informed written consent was received from all participants. All research was performed in accordance with the relevant guidelines and regulations. We performed a total 49 specimens, which based on the latest WHO classification represented 26 LEGH cases (age range, 32–62; median, 47), 12 GAS cases (age range, 41–77 years; median, 55), and 11 NNEG cases from patients with uterine corpus leiomyoma (age range, 38–54; median, 45)18. All 49 specimens were fixed in 10% buffered formalin and embedded in paraffin wax. H.E.-stained sections were assessed by light microscopy.

Information of each case clinicopathological factors was obtained through electronic medical records from hospital information system of the Shinshu University Hospital. Data included date at diagnosis, date of surgery, age, tumor histology, ascites cytology, regional lymph node, treatment and prognosis. Clinicopathological staging of 12 GAS patients was based on the International Federation of Gynecology and Obstetrics (FIGO) Staging System31. Regional lymph node dissection was performed in all but one patient, who could not be assessed for lymph node metastatic status. Survival of all 12 GAS patients was followed at Shinshu University Hospital. Overall survival (OS) period was defined as the length of the time during patient alive after surgical cancer resection. Progression free survival (PFS) period was defined as the length of time during a patient lives without cancer progression and/or recurrence after surgical cancer resection. Cancer progression and recurrence was diagnosed by clinicians on the basis of physical examination, imaging and scintigraphy.

Immunohistochemistry. The following primary antibodies were used: anti-α4GnT (I17K, polyclonal, 1:100 dilution), anti-αGlcNAc (clone HIK1083, 1:15, Kitokagaku, Tokyo, Japan), anti-MUC6 (clone CLH5, 1:100, Novocastra, Newcastle, UK) and anti-p16 (clone G175–405, 1:50; BD Biosciences, Franklin Lakes, NJ, USA). The anti-α4GnT antibody was previously prepared in our laboratory, and its specificity was validated by Western blot analysis and immunocytochemistry using gastric cancer AGS-α4GnT cells20. Three-micrometer-thick sections were deparaffinized in xylene and rehydrated in ethanol. Endogenous peroxidase activity was quenched by soaking sections in absolute methanol containing 0.3% hydrogen peroxide for 10 min. For anti-MUC6 and anti-p16, antigens were retrieved by boiling sections in a microwave in 10 mM Tris/HCl buffer (pH 8.0) containing 1 mM EDTA for 15 min. Sections were then exposed to primary antibodies at room temperature for 60 min. After 30 min incubation of secondary antibody at room temperature, the color reaction was developed with 3,3-diaminobenzidine (Djiidou, Kumamoto, Japan). Negative controls were established by omitting primary antibodies from the procedure. Sections were evaluated by K. Ida and K. Yamanobe. As for p16, lesions exhibiting diffuse nuclear staining of moderate or strong intensity in more than half of the cells were judged positive, as described32. Immunostaining of α4GnT was evaluated as positive when detected in the supranuclear region in a “dot-like” pattern24. αGlcNAc and MUC6 were evaluated based on cytosolic staining. Scoring of α4GnT, αGlcNAc and MUC6 expression was undertaken as follows. First, cases in which ≥10% of the total number of endocervical or tumor cells of each specimen were positively-stained were judged positive, as described previously18,33. Second, expression levels of α4GnT, αGlcNAc and MUC6 were further scored semi-quantitatively from 0 to 3: 0 (<10% positive cells), 1 (10–33% positive cells), 2 (34–66% positive cells), and 3 (≥67% positive cells), as described previously18,33.

Statistical analysis. Correlation between each stage (NNEG, LEGH and GAS) and the number of positive cases was analyzed by Fisher's exact probability test. Comparisons of semi-quantitative immunoreactivity scores of α4GnT, αGlcNAc or MUC6 at each stage were performed using the Kruskal–Wallis test with post-hoc pairwise comparison of subgroups. For GAS patients’ analysis, clinicopathological parameters were compared using the Fisher’s exact probability test. Survival curves were constructed using the Kaplan–Meier method, and the difference between curves was evaluated by a log–rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. All data analyses were performed using the Software Package for the Social Sciences (SPSS version 25; IBM, Armonk, NY, USA). P-values < 0.05 were considered statistically significant.

Compliance with ethical standards. This study was approved by the ethics committee of Shinshu University School of Medicine, Japan (project no. 3996 was approved on April 3, 2018).

Results

α4GnT, αGlcNAc and MUC6 expression in each histological type. MUC6 was positively expressed in all 26 LEGH cases, 10 of 12 GAS cases and 7 of 11 NNEG cases (Table 1). The frequency of MUC6 positivity differed significantly between NNEG and LEGH (P < 0.01), but not between LEGH and GAS (P = 0.09) (Table 1). α4GnT-positive cells largely co-localized with αGlcNAc-positive cells in all positive lesions (Fig. 2). In LEGH, α4GnT and αGlcNAc were highly expressed in all 26 and 25 of 26 cases, respectively (Table 1). In GAS, α4GnT and αGlcNAc were co-expressed in the same 5 of 12 cases (Table 1). In NNEG, neither α4GnT nor αGlcNAc were detectable in any case (Fig. 2 and Table 1). Frequencies of α4GnT and αGlcNAc positivity differed significantly between NNEG and LEGH and between LEGH and GAS (P < 0.001) (Table 1).

We next evaluated immunohistochemical scores from 0–3 (see Materials and Methods) of each marker including α4GnT, αGlcNAc and MUC6, in every case (Table S1) and compared differences among NNEG, LEGH and GAS histological types. The MUC6 score was high in all histological types: NNEG (median, 2.0 [interquartile range (IQR), 3.0]), LEGH (median, 3.0 [IQR, 0.0]), and GAS (median, 2.5 [IQR, 2.0], respectively). The MUC6 score differed significantly between LEGH and NNEG (P < 0.05), but not between LEGH and GAS (P = 0.103) (Fig. 3A). By contrast, both α4GnT and αGlcNAc scores were consistently lower in NNEG (median, 0.0 [IQR,
1.75], either), GAS (median, 0.0 [IQR, 1.75], and median, 0.0 [IQR, 2.75], respectively) than in LEGH (median, 3.0 [IQR, 1.0], either). Statistically, both \( \alpha \) 4GnT and \( \alpha \) GlcNAc scores in LEGH were significantly higher than those in NNEG (\( P < 0.001 \), either) in GAS (\( P = 0.01 \), either) (Fig. 3A).

We then compared these scores in each histological type (i.e., NNEG, LEGH and GAS). In NNEG cases, we observed significantly different \( \alpha \) 4GnT versus MUC6 as well as \( \alpha \) GlcNAc versus MUC6 scores (\( P < 0.001 \) for NNEG) (Fig. 3B), differences not apparent in LEGH cases (Fig. 3B). In GAS cases, only the \( \alpha \) 4GnT and MUC6 scores showed a significant difference (\( P < 0.05 \)) (Fig. 3B).

**Table 1.** Frequency of positive cases for MUC6, \( \alpha \) GlcNAc, \( \alpha \) 4GnT, and p16 expression in the NNEG, LEGH and GAS. *Significant difference in frequency of MUC6 positivity between NNEG and LEGH (\( P < 0.01 \)).**

**Association of HPV infection in all 49 specimens.** All NNEG, LEGH and GAS cases (49 cases) were p16 negative, which confirm that these 49 cases chosen for analysis were not derived from HPV infection (Table 1).

**Correlation between clinicopathological findings of GAS patients and \( \alpha \) 4GnT, \( \alpha \) GlcNAc and MUC6 expression.** In GAS patients, we did not observe significant differences in clinicopathological findings, such as patient age, FIGO stage, lymph node metastasis and ascites cytology, between cases positive or negative for MUC6, \( \alpha \) GlcNAc and \( \alpha \) 4GnT markers (Table 2). However, both \( \alpha \) 4GnT- and \( \alpha \) GlcNAc-positive cases consistently showed a lower frequency of lymph node metastasis and pelvic dissemination relative to negative cases (\( P = 0.175 \) for \( \alpha \) 4GnT, and \( P = 0.159 \) for \( \alpha \) GlcNAc) (Table 2). Furthermore, the frequency of lymph node metastasis in cases scoring 2 or 3 for \( \alpha \) GlcNAc expression was significantly lower than that in cases scored as 0 or 1 (\( P < 0.05 \)) (Table S2).

**Correlation between GAS patients survival and \( \alpha \) 4GnT, \( \alpha \) GlcNAc and MUC6 expression.** Median follow-up period was 33 months. Median overall survival (OS) was 33 months (range from 3 to 163 months). Median progression free survival (PFS) was 13 months (range from 1 to 51 months). During our

![Image of immunohistochemical expression of \( \alpha \) 4GnT, \( \alpha \) GlcNAc and MUC6 in NNEG, LEGH, and GAS (cases G-10 and G-5). Although \( \alpha \) 4GnT and \( \alpha \) GlcNAc are expressed in LEGH, their expression decreases in GAS. Note that overall \( \alpha \) 4GnT and \( \alpha \) GlcNAc are co-expressed in LEGH and GAS (case G-10), while MUC6 is expressed broadly in almost all histological types. Scale bar (bottom, right) = 100 \( \mu \)m. Insets show enlarged views of H.E. and \( \alpha \) 4GnT-stained sections. \( \alpha \) 4GnT in LEGH and GAS (case G-10) characteristically exhibits a “dot-like” pattern. Scale bar in inset (lower right) = 10 \( \mu \)m.
follow-up period, 2 of 12 GAS patients remained alive without cancer progression, while other 10 others died due to cancer progression.

In GAS patients, the estimated median survival of patients positive for both \(\alpha_4\text{GnT} \) and \(\alpha\text{GlcNAc} \) (\(n = 5\)) was 30 months, whereas that of the patients negative for both (\(n = 7\)) was 12 months. In addition, the median progression-free survival period of \(\alpha_4\text{GnT} \)- and \(\alpha\text{GlcNAc}-positive cases was 19 months, while that of \(\alpha_4\text{GnT}-\) and \(\alpha\text{GlcNAc}-negative cases was 4 months. Thus, patients positive for \(\alpha_4\text{GnT} \) and \(\alpha\text{GlcNAc} \) had significantly better prognosis relative to patients negative for both in OS rate and PFS (\(P < 0.05 \) for OS, and \(P < 0.01 \) for PFS) (Fig. 4). Relevant to MUC6 expression, we observed no significant differences in OS and PFS between positive and negative cases (\(P = 0.909 \) for OS, and \(P = 0.915 \) for PFS) (Fig. 4).

Table 2. Clinicopathologic parameters of GAS patients relative to \(\alpha\text{GlcNAc} \), \(\alpha_4\text{GnT} \) and MUC6 expression. \(^1\)Lymphnode dissection not performed in one case. GAS, gastric-type adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics.
Lastly we evaluated the relationship between clinicopathological factors including the $\alpha$GlcNAc and $\alpha$4GnT expression and OS or PFS on 12 GAS cases. Univariate analysis demonstrated that only $\alpha$GlcNAc and $\alpha$4GnT expression was significantly correlated with OS ($P = 0.045$), and $\alpha$GlcNAc and $\alpha$4GnT expression and lymph node metastasis status were significantly correlated with PFS ($P = 0.026$ and 0.032, respectively) (Table 3). Variables with $P$-values less than 0.150 in the univariate analysis were included in the multivariate analysis. Multivariate analysis identified that $\alpha$GlcNAc and $\alpha$4GnT expression is the only independent prognostic factor in OS as well as in PFS. FIGO stage and lymph node metastasis status were found not to be independent prognostic factors in OS as well as in PFS (Table 3).

Discussion

Here, we report that $\alpha$4GnT and $\alpha$GlcNAc expression patterns are overall consistent, that is, they are absent in NNEG, acquired in LEGH, and then slightly decrease as carcinogenesis progression to GAS. Furthermore, decreased $\alpha$4GnT and $\alpha$GlcNAc expression was significantly and positively correlated with malignant prognosis in GAS patients. By contrast, MUC6 expression levels were relatively high throughout the sequence from NNEG to LEGH to GAS (Figs 2, 3B).

Previously, we isolated human cDNA encoding $\alpha$4GnT, which catalyzes $\alpha$GlcNAc biosynthesis by transferring GlcNAc from UDP-GlcNAc to terminal $\beta$-galactose residues present in O-glycans with an $\alpha$1,4-linkage (Fig. 1).$^{26,27}$ $\alpha$4GnT protein is localized to the Golgi apparatus of gastric gland mucous cells, which corresponds to its expression as “dot-like” pattern (Fig. 2 and S1).$^{24}$ Our study suggests that $\alpha$GlcNAc biosynthesis is regulated by $\alpha$4GnT expressed in cells of the uterine cervix, given that $\alpha$4GnT-positive cells largely overlapped with $\alpha$GlcNAc-positive cells in most cases (Fig. 2 and Table 1). Immunohistochemical $\alpha$GlcNAc expression was often weak and difficult to be detected. On the other hand, $\alpha$4GnT expression was always distinct with a typical supranuclear dot-like pattern (Fig. S1). Thus, $\alpha$4GnT could serve as an alternative marker for $\alpha$GlcNAc.

It is noteworthy that neither $\alpha$GlcNAc nor $\alpha$4GnT was detected in NNEG (Figs 2, 3 and Table 1). By contrast, MUC6 expression was often observed in NNEG (Figs 2, 3 and Table 1). Because LEGH histology resembles that of NNEG, differential diagnosis of the two is sometimes problematic.$^{18}$ Our findings indicate that evaluation of $\alpha$GlcNAc or $\alpha$4GnT could be helpful in differentiating LEGH from NNEG. We previously observed $\alpha$GlcNAc, $\alpha$4GnT and MUC6 expression in normal pyloric glands of human stomach.$^{24}$ Here, we observe that MUC6 but not $\alpha$4GnT is frequently expressed in NNEG. In humans, chromosomal locations of MUC6 and $\alpha$4GnT are

![Overall survival (OS) and progression-free survival (PFS) curves of 12 GAS patients, based on phenotypic expression of $\alpha$4GnT, $\alpha$GlcNAc and MUC6 markers. Patients whose specimens are positive for $\alpha$4GnT and $\alpha$GlcNAc show more favorable prognosis (log-rank test, $P < 0.05$ for OS, $P < 0.01$ for PFS) (Left side figures). There are no significant differences in prognosis associated with differences in MUC6 expression (log-rank test, $P = 0.909$ for OS, $P = 0.915$ for PFS) (Right side figure).}
decreased expression of 4GnT. Molecular mechanisms underlying regulation of gastric type cervical tumor progression by 4GnT were investigated. 4. Mathew, A. & George, P. S. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix – analysis of α 4GnT expression is an independent prognostic factor for GAS patients (Table 3). GAS is a rare tumor, and number of GAS patients is much more than NNEG. Thus, further investigation will be of great significance to accumulate more number of GAS patients to consolidate the prognostic significance of α 4GnT expression.

### Table 3. Results of univariate and multivariate analysis of possible prognostic factors for GAS

| Factors                        | Univariate       | Multivariate     |
|-------------------------------|------------------|------------------|
|                               | HR (95% CI)      | P                | HR (95% CI)     | P                |
| Overall survival (n = 120)    |                  |                  |                 |                  |
| αGlcNAc/αGnT Positive vs negative | 0.194 (0.039–0.964) | 0.045*           | 0.126 (0.020–0.788) | 0.027*           |
| MUC6 Positive vs negative     | 1.101 (0.213–5.695) | 0.909            |                  |                  |
| FIGO stage I-II vs III-IV     | 0.307 (0.067–1.414) | 0.130            | 0.162 (0.025–1.049) | 0.056            |
| Age <55 vs ≥55                | 0.351 (0.064–1.932) | 0.229            |                  |                  |
| Lymphnode metastasis Negative vs positive | 0.411 (0.097–1.750) | 0.229            |                  |                  |
| Ascitic cytology Negative vs positive | 0.501 (0.026–0.958) | 0.357            |                  |                  |
| Progression-free survival (n = 120) |                  |                  |                 |                  |
| αGlcNAc/αGnT Positive vs negative | 0.089 (0.010–0.752) | 0.026*           | 0.093 (0.009–0.984) | 0.048*           |
| MUC6 Positive vs negative     | 0.920 (0.189–4.470) | 0.918            |                  |                  |
| FIGO stage I+II vs III+IV     | 0.290 (0.058–1.455) | 0.133            | 0.140 (0.018–1.092) | 0.061            |
| Age <55 vs ≥55                | 0.884 (0.237–3.305) | 0.855            |                  |                  |
| Lymphnode metastasis Negative vs positive | 0.159 (0.030–0.854) | 0.032*           | 0.284 (0.046–1.736) | 0.173            |
| Ascitic cytology Negative vs positive | 1.319 (0.352–4.935) | 0.681            |                  |                  |

In conclusion, our work indicates that αGlcNAc catalyzed by α4GnT is relevant to two important developments in uterine cervix tumor, gastric type: one a positive correlation with the transition to LEGH from NNEG. The other a negative correlation with tumor progression from LEGH to GAS and unfavorable progression in GAS. However, molecular function of α4GnT in tumor progression remains to be clarified. Our immunohistochemical analysis of α4GnT and αGlcNAc expression in cervical resected specimens provides important tools for diagnosis of uterine cervical tumor, gastric type, and promotes understanding of tumor development. Both α4GnT and αGlcNAc are useful biomarkers for diagnosis of LEGH in uterine cervical biopsy specimens. Furthermore, decreased expression of α4GnT and αGlcNAc in follow-up biopsy of LEGH patients’ uterine cervix was closely associated with tumor progression to unfavorable GAS. Further studies will of great significance to address molecular mechanisms underlying regulation of gastric type cervical tumor progression by α4GnT.

### References

1. Adegoke, O., Kulasingam, S. & Virnig, B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health. 21, 1031–1037 (2012).
2. Wang, S. S. et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000. Cancer. 100, 1035–1044 (2004).
3. Smith, H. O. et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study. Gynecol Oncol. 78, 97–105 (2000).
4. Mathew, A. & George, P. S. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix – worldwide. Asian Pac J Cancer Prev. 10, 645–650 (2009).
5. Shiliang, L., Semenciw, R. & Mao, Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. *CMAJ* **164**, 1151–1152 (2001).

6. Pimenta, J. M. *et al.* Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. *BMC Cancer* **553**, 10, 1186/1471-2407-13-533 (2013).

7. Piróg, E. C. *et al.* HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. *Mod Pathol.* **27**, 1559–1567 (2014).

8. Piróg, E. C. *et al.* Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. *Am J Pathol.* **157**, 1055–1062 (2000).

9. Holl, K. *et al.* Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: results from a European multinational epidemiological study. *Int J Cancer.* **137**, 2858–2868 (2015).

10. Park, K. J. *et al.* Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. *Am J Surg Pathol.* **35**, 633–646 (2011).

11. Xu, J. Y. *et al.* Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. *Int J Gynecol Pathol.* **24**, 296–302 (2005).

12. Kusano, T. *et al.* Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. *Am J Pathol.* **177**, 2169–2175 (2010).

13. Kojima, A. *et al.* Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. *Am J Surg Pathol.* **31**, 664–672 (2007).

14. Karamurzin, Y. S. *et al.* Gastric-type endocervical adenocarcinoma. An aggressive tumour with unusual metastatic patterns and poor prognosis. *Am J Surg Pathol.* **39**, 1449–1457 (2015).

15. Nucci, M. R., Clement, P. B. & Young, R. H. Lobular endocervical glandular hyperplasia, not otherwise specified: a clinicopathologic analysis of thirteen cases of a distinctive pseudoneoplastic lesion and comparison with fourteen cases of adenoma malignum. *Am J Surg Pathol.* **23**, 886–891 (1999).

16. Mikami, Y., Hata, S., Melamed, J., Fujiwara, K. & Manabe, T. Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype. *Histopathology.* **39**, 364–372 (2001).

17. Ishii, K., Ota, H. & Katsuyama, T. Lobular endocervical glandular hyperplasia represents pyloric gland metaplasia? *Am J Surg Pathol.* **24**, 323 (2000).

18. Kurman R. J. *et al.* editors. WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon: IARC (2014).

19. Mikami, Y. & McCluggage, W. G. Endocervical glandular lesions exhibiting gastric differentiation: an emerging spectrum of benign, premalignant, and malignant lesions. *Adv Anat Pathol.* **20**, 227–237 (2013).

20. Takatsu, A. *et al.* Cholinergic analysis suggests that STK11 gene mutations are involved in progression of lobular endocervical glandular hyperplasia (LEGH) to minimal deviation adenocarcinoma (MDA). *Virchows Arch.* **462**, 645–651 (2013).

21. Ishihara, K. & et al. Peripherally α-linked N-acetylgalactosamine on the carbohydrate moiety of mucin derived from mammalian gastric gland mucous cells: epitope recognized by a newly characterized monoclonal antibody. *Biochem J.* **318**, 409–416 (1996).

22. Shiratsu, K., Higuchi, K. & Nakayama, J. Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach. *Cancer Sci.* **105**, 126–133 (2014).

23. Yamanoi, K., Sekine, S., Higuchi, K., Kusuma, R. & Nakayama, J. Decreased expression of gastric gland mucin-specific glycans α1,4-linked N-acetylgalactosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach. *Histopathology.* **67**, 898–904 (2015).

24. Zhang, M. X. *et al.* Immunohistochemical demonstration of α1,4-N-acetylgalactosaminyltransferase that forms GlcNAcα1,4Galβ3 residues in human gastrointestinal mucosa. *J Histochem Cytochem.* **49**, 587–596 (2001).

25. Yamanoi, K. & Nakayama, J. Reduced αGalNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett’s adenocarcinoma, and pancreatic cancer. *Histochem Cell Biol.* **149**, 569–575 (2018).

26. Nakayama, J., Yeh, J. C., Misra, A. K., Ito, S. & Katsuyama, T. FukudaM. Expression cloning of a human α1,4-N-acetylgalactosaminyltransferase that forms GlcNAcα1–4Galβ3 in human gastrointestinal mucosa. *Am J Physiol Gastrointest Liver Physiol.* **295**, G670–G676 (2008).

27. Matsuzawa, K., Akamatsu, T. & Katsuyama, T. Mucin histochemistry of pancreatic duct cell carcinoma, with special reference to glandular differentiation and phenotype. *Virchows Arch.* **467**, 305–311 (2018).

28. Prat, J. *et al.* FIGO Committee on Gynecologic Oncology: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet.* **124**, 1–5 (2014).

29. Matsuzawa, K. & et al. Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations. *Am J Surg Pathol.* **30**, 370–376 (2014).

30. Matsuzawa, K., Akamatsu, T. & Katsuyama, T. Gastric mucin histochemistry and phenotype of pancreatic duct cell carcinoma, with special reference to glandular differentiation. *Hum Pathol.* **23**, 925–933 (1992).

31. Prat, J. *et al.* Complete genomic organization of the human MUC6 and MUC2 mucin genes. *Genomics.* **83**, 936–939 (2004).

Acknowledgements

The authors thank Ms. Yoshiko Sato for technical advice relevant to immunostaining, and also thank Dr. Elise Lamar for editing the manuscript. This study was founded by Grants-in-Aid for Scientific Research 15H04712 (J.N.), 17K15640 (K.Y.) and 19K16555 (K.Y.) from the Japan Society for the Promotion of Science.

Author Contributions

K.I., K.Y., S.A., T.M. and J.N. participated in the study design, K.I., S.A., H.T., T.M. and T.S. collected the samples, K.I. and K.Y. performed the experiments, K.I., K.Y. and T.M. discussed the results and completed the analysis and K.I., K.Y. and J.N. drafted the manuscript. All authors contributed to reviewing the manuscript and were involved in critical discussion.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-49376-7.

Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019